OncoZenge AB (FRA:8LY) Other Financing: €-0.77 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8LY OncoZenge AB FRA:8LY
26 GF Score
Price €0.60
! 2 Warning Signs
View Full Analysis

What is OncoZenge AB Other Financing?

OncoZenge AB FRA:8LY +1.34% 26 Other Financing is €-0.77 Mil as of Mar. 2026. GuruFocus rates FRA:8LY with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

OncoZenge AB's Other Financing for the three months ended in Mar. 2026 was €-0.09 Mil.

OncoZenge AB's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.77 Mil.

OncoZenge AB Other Financing Historical Data

* Premium members only.

The historical data trend for OncoZenge AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoZenge AB Other Financing Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -0.06

OncoZenge AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.68 0.00 -0.09
FRA:8LY
26GF Score
OncoZenge AB FRA:8LY
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoZenge AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-0.77 Mil mean?
OncoZenge AB (FRA:8LY) has a Other Financing of €-0.77 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for OncoZenge AB and its competitors.
Is OncoZenge AB's Other Financing too high?
OncoZenge AB's current Other Financing is €-0.77 Mil. Overall, OncoZenge AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does OncoZenge AB's Other Financing compare to VRTX and REGN?
OncoZenge AB's Other Financing of €-0.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for OncoZenge AB and its competitors. OncoZenge AB's current Other Financing is €-0.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoZenge AB stock overvalued right now?
OncoZenge AB (FRA:8LY) has a current Other Financing of €-0.77 Mil. The current Other Financing is €-0.77 Mil. OncoZenge AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For OncoZenge AB (FRA:8LY), the current Other Financing is €-0.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoZenge AB Business Description

Other Exchanges ONCOZ:Sweden
Address Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score

Get the complete analysis for FRA:8LY

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price